The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Phil Newsome is Professor of Hepatology, Director of the Centre for Liver and Gastrointestinal Research at the University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital in Birmingham, United Kingdom. Professor Newsome is also the Deputy Director for the Birmingham NIHR Biomedical Research Centre (BRC) and the Director of the Midlands & Wales Advanced Therapy Treatment Centre.
Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD.
He has published 198 papers (99 since 2016). Cited 11280 times; h index of >50. Raised >£50M in grant income with £20M active funding.
He undertook pivotal studies on community prevalence (J.Hep 2012) and natural history (Gastroenterology 2020) and developed new strategies for determining NAFL severity (Gastro 2020/Lancet GH 2020 – FAST score). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He is an editor of a recently published textbook on Liver Transplantation, chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.
Professor Newsome’s research portfolio has led to high impact publications throughout, including both original articles (NEJM, PNAS, Gastroenterology, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet, Nature and Nature Comms) and review articles (FASEB, Gastroenterology, Journal of Hepatology).